Surya Bhatt, M.D., an associate professor in the UAB Division of Pulmonary, Allergy, and Critical Care Medicine, reported in the New England Journal of Medicine that patients with COPD and type 2 ...
Medpage Today on MSN1mon
Dupilumab Improves Quality of Life for COPD PatientsBOSTON -- Patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation had greater improvements in ...
HealthDay on MSN1mon
CHEST: Dupilumab for COPD Tied to Improvement in Health-Related Quality of LifeMONDAY, Oct. 7, 2024 (HealthDay News) -- Dupilumab improves health-related quality of life (HRQoL) in patients with chronic ...
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
in China has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils.
(dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils. Specifically, the approval covers ...
has approved Dupixent ® (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Dupixent is ...
chronic spontaneous urticaria and COPD in different age populations. More than 1,000,000 patients are being treated with Dupixent globally. Dupilumab is being jointly developed by Regeneron and Sanofi ...
Second Phase 3 Clinical Trial Again Shows Dupilumab Lessens Disease in COPD Patients With Type 2 Inflammation May 20, 2024 — Chronic obstructive pulmonary disease patients with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback